Genmab A/S (NASDAQ:GMAB) Stock Sees Unusually High Call Option Buying

Genmab A/S Sponsored ADR (NASDAQ:GMAB) was the target of unusually large options trading on Thursday. Traders acquired 24,213 call options on the company. This is an increase of 485% compared to the typical daily volume of 4,137 call options.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds have recently bought and sold shares of the company. First Trust Advisors LP raised its stake in Genmab A/S by 17.0% in the 3rd quarter. First Trust Advisors LP now owns 3,225,639 shares of the company’s stock valued at $115,075,000 after acquiring an additional 469,117 shares during the period. Independent Advisor Alliance bought a new stake in shares of Genmab A/S during the 3rd quarter valued at about $150,000. Global Retirement Partners LLC grew its stake in Genmab A/S by 52.8% in the 3rd quarter. Global Retirement Partners LLC now owns 5,607 shares of the company’s stock worth $200,000 after buying an additional 1,938 shares in the last quarter. Bessemer Group Inc. increased its stake in Genmab A/S by 38.6% in the third quarter. Bessemer Group Inc. now owns 729 shares of the company’s stock valued at $26,000 after acquiring an additional 203 shares during the last quarter. Finally, Hantz Financial Services Inc. raised its holdings in shares of Genmab A/S by 37.2% during the 3rd quarter. Hantz Financial Services Inc. now owns 30,051 shares of the company’s stock valued at $1,072,000 after buying an additional 8,146 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Down 2.8%

GMAB stock traded down $1.51 during mid-day trading on Thursday, reaching $52.35. 3,495,348 shares of the company traded hands, compared to its average volume of 2,558,773. The stock has a market cap of $32.67 billion, a price-to-earnings ratio of 44.75, a P/E/G ratio of 2.18 and a beta of 0.73. The company has a quick ratio of 2.43, a current ratio of 2.45 and a debt-to-equity ratio of 0.74. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $59.97. The firm’s 50 day moving average price is $40.46 and its 200 day moving average price is $31.43.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, November 5th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.20. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.20 billion. As a group, equities research analysts predict that Genmab A/S will post 1.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Morgan Stanley boosted their price objective on Genmab A/S from $42.00 to $57.00 and gave the company an “equal weight” rating in a report on Friday, October 30th. HC Wainwright increased their target price on Genmab A/S from $50.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Weiss Ratings raised shares of Genmab A/S from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday. Truist Financial reissued a “buy” rating and issued a $67.00 price target (up from $45.00) on shares of Genmab A/S in a research report on Thursday, October 29th. Finally, New Street Research set a $43.00 price target on shares of Genmab A/S in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Genmab A/S has an average rating of “Buy” and a consensus target price of $53.61.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.